Terms: = Breast cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
2694 results:
1. The diagnostic value of multimodal imaging based on MR combined with ultrasound in benign and malignant breast diseases.
Bai D; Zhou N; Liu X; Liang Y; Lu X; Wang J; Liang L; Wang Z
Clin Exp Med; 2024 May; 24(1):110. PubMed ID: 38780895
[TBL] [Abstract] [Full Text] [Related]
2. Calcium-sensing Receptor, a Potential Biomarker Revealed by Large-scale Public Databases and Experimental Verification in Metastatic breast cancer.
Xie W; Xu H; Cheng Y; Lin X; Zeng J; Sun Y
Technol Cancer Res Treat; 2024; 23():15330338241254219. PubMed ID: 38780484
[TBL] [Abstract] [Full Text] [Related]
3. Survival Predictive Nomograms for Non-Surgical Brain Metastases Patients From Non-Small Cell Lung cancer Receiving Radiotherapy: A Population-Based Study.
Li P; Luo J; Zheng Z; Meng L; Zhang A; Cao W; Gong X
Cancer Control; 2024; 31():10732748241255212. PubMed ID: 38769789
[TBL] [Abstract] [Full Text] [Related]
4. Natural History and Prognostic Model of Untreated Papillary Thyroid cancer: A SEER Database Analysis.
Wang D; Yang Y; He Y; Yang H; Yang L
Cancer Control; 2024; 31():10732748241253956. PubMed ID: 38756002
[TBL] [Abstract] [Full Text] [Related]
5. Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
Zhang X; Teng X; Zhang J; Lai Q; Cai J
Breast Cancer Res; 2024 May; 26(1):77. PubMed ID: 38745321
[TBL] [Abstract] [Full Text] [Related]
6. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery.
Sturniolo I; Váróczy C; Bede ÁM; Hegedűs C; Demény MÁ; Virág L
J Vis Exp; 2024 Apr; (206):. PubMed ID: 38738886
[TBL] [Abstract] [Full Text] [Related]
7. Preexisting Diabetes and breast cancer treatment Among Low-Income Women.
Bekele BB; Lian M; Schmaltz C; Greever-Rice T; Shrestha P; Liu Y
JAMA Netw Open; 2024 May; 7(5):e249548. PubMed ID: 38717774
[TBL] [Abstract] [Full Text] [Related]
8. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
9. The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
Wang J; Tian C; Zheng BJ; Zhang J; Jiao DC; Qu JR; Liu ZZ
BMC Cancer; 2024 May; 24(1):549. PubMed ID: 38693523
[TBL] [Abstract] [Full Text] [Related]
10. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy.
Ascheid D; Baumann M; Pinnecker J; Friedrich M; Szi-Marton D; Medved C; Bundalo M; Ortmann V; Öztürk A; Nandigama R; Hemmen K; Ergün S; Zernecke A; Hirth M; Heinze KG; Henke E
Nat Commun; 2024 Apr; 15(1):3599. PubMed ID: 38678014
[TBL] [Abstract] [Full Text] [Related]
11. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract] [Full Text] [Related]
12. Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project.
Potter S; Avery K; Ahmed R; de Boniface J; Chatterjee S; Dodwell D; Dubsky P; Iwata H; Jiang M; Lee HB; MacKenzie M; Poulakaki F; Richardson AL; Sepulveda K; Spillane A; Thompson AM; Werutsky G; Wright JL; Zdenkowski N; Cowan K; McIntosh S
BMJ Open; 2024 Apr; 14(4):e084488. PubMed ID: 38643011
[TBL] [Abstract] [Full Text] [Related]
13. cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
[TBL] [Abstract] [Full Text] [Related]
14. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract] [Full Text] [Related]
15. BRCA2 Polymorphisms and breast cancer Susceptibility: a Multi-Tools Bioinformatics Approach.
Jan H; Khan NU; Al-Qaaneh AM; Tasleem M; Almutairi MH; Ali I
Cell Physiol Biochem; 2024 Mar; 58(2):128-143. PubMed ID: 38623065
[TBL] [Abstract] [Full Text] [Related]
16. Differentiation of invasive ductal and lobular carcinoma of the breast using MRI radiomic features: a pilot study.
Maiti S; Nayak S; Hebbar KD; Pendem S
F1000Res; 2024; 13():91. PubMed ID: 38571894
[TBL] [Abstract] [Full Text] [Related]
17. Development and validation of a nomogram for predicting lymph node metastasis in ductal carcinoma in situ with microinvasion: A SEER population-based study.
Zhu K; Sui Y; Zhu M; Gao Y; Yuan Y; Sun P; Meng L; Dai J; Li Z
PLoS One; 2024; 19(4):e0301057. PubMed ID: 38557552
[TBL] [Abstract] [Full Text] [Related]
18. Wireless electrostimulation for cancer treatment: An integrated nanoparticle/coaxial fiber mesh platform.
Resina L; Garrudo FFF; Alemán C; Esteves T; Ferreira FC
Biomater Adv; 2024 Jun; 160():213830. PubMed ID: 38552500
[TBL] [Abstract] [Full Text] [Related]
19. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
20. Exploration of a noninvasive radiomics classifier for breast cancer tumor microenvironment categorization and prognostic outcome prediction.
Han X; Gong Z; Guo Y; Tang W; Wei X
Eur J Radiol; 2024 Jun; 175():111441. PubMed ID: 38537607
[TBL] [Abstract] [Full Text] [Related]
[Next]
